<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03380559</url>
  </required_header>
  <id_info>
    <org_study_id>P160926J</org_study_id>
    <secondary_id>2017-001709-33</secondary_id>
    <nct_id>NCT03380559</nct_id>
  </id_info>
  <brief_title>A Phase III Study to Evaluate Efficacy of Botulinum Toxin for Treating Epicondylitis</brief_title>
  <acronym>EPITOX</acronym>
  <official_title>A Phase III Randomized Double-blind Study to Evaluate Efficacy of Botulinum Toxin for Treating Epicondylitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assistance Publique - Hôpitaux de Paris</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assistance Publique - Hôpitaux de Paris</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study aims to demonstrate that intramuscular injection of botulinum toxin with a
      paralyzing dose coupled with subcutaneous injection of corticoid has greater efficacy than
      corticoid injection only or toxin injection only for treating lateral epicondylitis in
      reducing pain at 6 months.

      As secondary objectives, the study aims to

        -  demonstrate improvement of quality of patient's life and positive effect on their
           resuming to professional activities or sportive activities.

        -  evaluate tolerance of treatment by grip strength measurement and adverse event
           collection.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a prospective multicenter phase IIIb randomized double-blind placebo-controlled
      study, to compare efficacy and tolerance of 3 groups of treatments for epicondylitis.

      All patients will be randomized in 3 following parallel treatment groups:

      Group A : botulinum toxin + corticoid

      Group C : placebo of toxin + corticoid

      Group T : botulinum toxin + placebo corticoid

      The study will be performed in 4 centers in France, targetting 150 patients. The follow-up of
      each patient will last 6 months after treatment.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">January 2018</start_date>
  <completion_date type="Anticipated">June 2021</completion_date>
  <primary_completion_date type="Anticipated">June 2021</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Ratio 1:1:1</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Variation of pain intensity between injection of treatment and 6 months after injection</measure>
    <time_frame>At the moment of injection</time_frame>
    <description>Evaluate the variation of muscle pain intensity in wrist extensor contractions between the moment of injection and the end of the 6th month with the Visual Analogue Scale (VAS).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Variation of pain intensity between injection of treatment and 6 months after injection</measure>
    <time_frame>6 months after injection</time_frame>
    <description>Evaluate the variation of muscle pain intensity in wrist extensor contractions between the moment of injection and the end of the 6th month with the VAS.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Spontaneous pain intensity at rest</measure>
    <time_frame>Before injection, 3 months after injection and 6 months after injection</time_frame>
    <description>Evaluate pain intensity at rest with the VAS.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain intensity of motion of wrist flexion</measure>
    <time_frame>Before injection, 3 months after injection and 6 months after injection</time_frame>
    <description>Evaluate pain intensity of motion of wrist flexion with the VAS.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain intensity at proximal insertion palpation on epicondylitis muscle</measure>
    <time_frame>Before injection, 3 months after injection and 6 months after injection</time_frame>
    <description>Evaluate pain intensity at proximal insertion palpation on epicondylitis muscle. The palpation will be under ultrasound control.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of days of sick leave</measure>
    <time_frame>6 months after injection</time_frame>
    <description>Number of days of sick leave will be noted and collected</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The percentage of patients returning to professional activity or sportive activity</measure>
    <time_frame>6 months after injection</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Measurement of prehensile grasp capabilities by a force</measure>
    <time_frame>At baseline, 3 months after injection, 6 months after injection</time_frame>
    <description>The force will be measured by Jamar Hydraulic hand dynamometer.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Functional outcome after injection</measure>
    <time_frame>At baseline, 3 months after injection, 6 months after injection</time_frame>
    <description>Outcome will be evaluated by questionnaire Patient Rated Tennis Elbow Evaluation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anxiety and depression tests</measure>
    <time_frame>At baseline, 3 months after injection, 6 months after injection</time_frame>
    <description>Hospital Anxiety and Depression scale will be used</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequence and gravity of adverse events</measure>
    <time_frame>At baseline, 3 months after injection, 6 months after injection</time_frame>
    <description>Adverse events will be collected and their severity will be reported.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Epicondylitis</condition>
  <arm_group>
    <arm_group_label>Group A : Association (botulinum toxin + corticoid)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Group C : placebo of toxin + corticoid :</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Group T : botulinum toxin + placebo corticoid</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Injection, botulinum toxin + corticoid</intervention_name>
    <description>Intramuscular injection of botulinum toxin (Xeomin® 100 U) under ultrasound control
Subcutaneous injection (lateral epicondylitis side) of corticoid (2 ml of Hydrocortancyl® 2,5 %)</description>
    <arm_group_label>Group A : Association (botulinum toxin + corticoid)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Injection, placebo of toxin + corticoid</intervention_name>
    <description>Intramuscular injection of placebo botulinum toxin (2 ml) under ultrasound control
Subcutaneous injection (lateral epicondylitis side) of corticoid (2 ml of Hydrocortancyl® 2,5 %)</description>
    <arm_group_label>Group C : placebo of toxin + corticoid :</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Injection, botulinum toxin + placebo corticoid</intervention_name>
    <description>Intramuscular injection of botulinum toxin (2 ml) under ultrasound control
Subcutaneous injection (lateral epicondylitis side) of placebo of corticoid (2 ml of physiological saline solution NaCL 0.9 %)</description>
    <arm_group_label>Group T : botulinum toxin + placebo corticoid</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient aged between 18 and 60 years;

          -  Physical disability or not;

          -  Unilateral lateral epicondylitis more than 3 months, recurrent or not, no response to
             at least one standard treatment such as: local injection of corticoid, physiotherapy,
             rest, NSAIDs per os;

          -  Signed consent obtained;

          -  Covered by health insurance.

        Exclusion Criteria:

          -  Central nervous system disorders result in spasticity in epicondylitis limb;

          -  History of severe psychiatric disorder;

          -  History of myasthenia gravis;

          -  Pregnant or breastfeeding woman;

          -  Unable to understand or respond to questions;

          -  Contraindication to botulinum toxin or corticoid;

          -  Treatment with botulinum toxin 3 months prior to baseline;

          -  Anticoagulant theraphy;

          -  Difficult to follow-up in the study;

          -  Patient under guardianship, or deprived of liberty by a judicial order.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>François Genêt, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Service de Médecine Physique et de Réadaptation Hôpital Raymond Poincaré</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>François Genêt, MD, PhD</last_name>
    <phone>+ 33 1 47 10 70 68</phone>
    <email>francois.genet@aphp.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Service de Médecine Physique et de Réadaptation, Hôpital Raymond Poincaré</name>
      <address>
        <city>Garches</city>
        <state>Hauts-de-Seine</state>
        <zip>92380</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>November 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 11, 2017</study_first_submitted>
  <study_first_submitted_qc>December 20, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">December 21, 2017</study_first_posted>
  <last_update_submitted>December 20, 2017</last_update_submitted>
  <last_update_submitted_qc>December 20, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">December 21, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Epicondylitis</keyword>
  <keyword>Botulinum toxin</keyword>
  <keyword>Corticoid</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tennis Elbow</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Botulinum Toxins</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

